Table 2—

Epidemiological data on hypoglycemia in type 2 diabetes, expressed as prevalence

StudyJennings, Wilson, and Ward, 1989 (ref. 75)U.K. Prospective Diabetes Study 33, 1998 (ref. 2)Hepburn, 1993 (ref. 83)*VA CSDM, 1995(ref. 74)Miller et al., 2001(ref. 76)Henderson et al., 2003 (ref. 82)*Leese et al., 2003 (ref. 79)Donnelly et al., 2005 (ref. 81)*
DesignRetrospective, structured interviewProspective multicentre randomized clinical trialRetrospective, questionnaireProspective multicenter randomized clinical trialRetrospective, interviewRetrospective questionnairePopulation-based dataset analysisProspective
SubjectsType 2 diabetes, oral antidiabetic agents onlyType 2 diabetes, oral antidiabetic agents and insulinTypes 1 and 2 diabetes, insulin onlyAll type 2 diabetesType 2 diabetesInsulin-treated type 2 diabetesMixed type 1 and type 2 diabetic subjects, oral antidiabetic agents and insulinInsulin-treated type 1 and type 2 diabetic subjects
Number219 (sulfonylurea 203, metformin 16)3,935104 type 1 and 104 type 2 diabetic subjects1531,05521516094 type 1 and 173 type 2 diabetic subjects
Age59 (40–65)54 ± 863 ± 960 ± 660.9 ± 0.4 (means ± SE)68 (27–87)53.8 (50.8–56.9)66 (34–86)
A1C %6.2 ± 1.29.3 ± 1.87.6 ± 0.1 (means ± SE)8.6 ± 1.57.85 (7.57–8.14)8.9 ± 1.41
HbA1%Subjects with hypoglycemia 9.5 ± 9, subjects without hypoglycemia 11.4 ± 3.010.3 ± 2
Duration6 months10 years1 year18–35 months7 months1 year1 year1 month
Definition of severe hypoglycemiaNAThird party assistanceThird party assistanceThird party assistance/LOC/fitThird party assistanceThird party assistanceNeed for parenteral treatment by emergency servicesThird party assistance
Oral antidiabetic agents: all hypoglycemiaMetformin 0%, sulfonylurea 20.2% (glyburide 31.3%, chlorpropamide 13.6%, gliclazide 13.1%)Glyburide 17.0%, chlorpropamide 11.0%NANA16%NANANA
Oral antidiabetic agents: severe hypoglycemiaGlyburide 0.6%, chlorpropamide 0.4%NANA0%NA0.8%NA
Insulin: all hypoglycemiaNA36.5%82.7%56% (conventional), 93% (intensive)30%64%NA45%
Insulin: severe hypoglycemiaNA2.3%10%NA0%15%7.3%3%
Main criticismsRecall bias for mild hypoglycemiaAtypical intensively managed group. Under-recording of eventsAll male, intensively managedRecall bias. Mainly female African AmericansRecall bias for mild hypoglycemiaOnly assessed hypoglycemia requiring emergency servicesShort duration
  • Data are means ± SD or median (range), unless otherwise indicated. LOC, loss of consciousness; NA, not applicable; VA CSDM, Veterans Affairs Cooperative Study in Type 2 Diabetes.

  • *

    * Only figures for type 2 diabetes given.